Introduction
My assignment, to provide an overview of proteoglycan (PG) research over several decades, has been a challenge. I have been around for a long time, my first contacts with the field, as a graduate student, dated back to the early 1960's, and so I should preferably be able to relate to trends and specific events with reasonably accurate indication of time. Unfortunately, I never kept a diary. In these early days PGs were not recognized as distinct molecular entities -the development of the area since has been truly amazing. I will attempt to highlight some of the key aspects of this process, though without any ambition to provide a comprehensive historical account. Also, I apologize at the outset for arbitrariness in selection of topics and references. For simplicity, the account will be restricted to PGs with hexuronic acid-containing glycosaminoglycans (GAGs); keratan sulfate will not be considered.
The proteoglycan concept
In the beginning there was chaos. While the existence of "proteinpolysaccharide complexes", as in cartilage, was recognized, the nature of such complexes was unknown. Ultracentrifugation of cartilage extracts yielded highly disperse fractions of varying protein contents and unclear molecular organization (Pal et al., 1966) . A covalent association, first suggested by the demonstration of serine residues bound to chondroitin sulfate (CS) chains (Muir, 1958) was established, and the -GlcA-Gal-Gal-Xyl-"linkage region" connecting serine residues to GAG chains was identified (Rodén and Smith, 1966; Kjellén and Lindahl, 1991) . The cartilage puzzle was resolved through experiments involving novel isolation and fractionation techniques that revealed the CSPG monomer ('aggrecan'), the macromolecular organization of CSPG-hyaluronan (at that time, hyaluronic acid, HA) complexes, and novel routes toward isolation of PGs from a variety of tissues (Sajdera and Hascall, 1969; Hardingham and Muir, 1974; Hascall and Heinegård, 1974) . A detailed account of subsequent progress and resultant identification of distinct PG species would fall outside the scope of this presentation, but can be found in various reviews (Hassell et al., 1986; Kjellén and Lindahl, 1991; Bernfield et al., 1999; Perrimon and Bernfield, 2001) .
The emergence of different PGs raised novel conceptual problems, including one of the nomenclatures that was dealt with at one of the early Gordon Conferences on Proteoglycans in the 1980's. Recognizing the GAG chains as the "business end" of PGs, some scientists argued against a nomenclature based on trivial names relating to core proteins. A proposal that PGs should be classified according to their constituent GAG chains, along with numbers referring to type of core protein was turned down by the majority of the conference attendants -in retrospect a sign of foresight. Importantly, PGs were found to be associated with, or intercalated in the plasma membrane of cells (Kraemer, 1971; Kjellén et al., 1981) . We now know that certain core proteins, such as syndecans, may carry both CS and heparan sulfate (HS) type GAG chains, and that the structures of GAG chains, by and large, appear independent of core-protein type (however, see (Li et al., 2011) ), but also, that many functional properties of such chains are strongly influenced by the associated core protein. The identified PGs increased in number and were classified with regard to locationintracellular, at the cell surface or in the extracellular matrix. Different modes of cell-surface association were detected, based on transmembrane peptide or glycosylphosphatidylinositol (GPI) anchors (David, 1993) . The inconsistent GAG substitution of "part-time PGs" raised the question as to what structural features of a protein qualify for PG status, a still unresolved issue. This problem is particularly intriguing considering that less than 20 distinct mammalian HSPG core proteins have been identified so far. Core protein structure apparently dictates the type of GAG attached (Chen and Lander, 2001) , rather than GAG fine structure. So, what is the current state of GAG structural analysis, and how do we perceive the mechanisms behind their biosynthesis?
Glycosaminoglycan structure and biosynthesis
Elucidating the structures of GAG chains has been a slow and still evolving process. Levels of complexity range from hyaluronan (HA) composed of uniform repeating disaccharide units, over CS and dermatan sulfate (DS) type chains with sulfate substituents in various but relatively uniformly distributed positions, to the highly complex substitution/epimerization pattern and domain organization of HS (Kjellén and Lindahl, 1991; Murphy et al., 2004) . Structural analysis was generally initiated by partially degrading GAGs to di-and oligosaccharides through various chemical and enzymatic procedures. Analytical methods employed were initially dominated by paper chromatography and electrophoresis, but subsequently included various column chromatographic procedures as well as NMR analysis of intact GAGs or oligosaccharides, including conformational aspects (Hricovíni et al., 2002) . Following identification of major disaccharide building blocks, rare structures involving sulfate groups in unusual positions or constellations were revealed in HS/heparin (Casu and Lindahl, 2001) as well as in CS/DS (Clement et al., 1998; Bao et al., 2005; Fongmoon et al., 2007) type GAGs. Methods emerged for analyzing GAG oligosaccharide sequence, based on chemoenzymatic degradation (Merry et al., 1999; Kreuger et al., 2005) or, more recently, mass spectrometry (Ly et al., 2011; Zaia, 2013) . So far application of these methods to native samples indicated, as predicted, that sulfate substituents may preferentially occupy certain positions, but not (in my opinion -this issue remains somewhat controversial) that the resultant patterns can be interpreted in terms of fixed sequences. Moreover, no template-driven process has been discovered to account for the formation of such sequences. We will move on to summarizing the research leading to our present understanding of GAG biosynthesis.
Pioneering studies by Silbert identified the appropriate UDP-sugar and PAPS precursors required to generate heparin-and CS-like polymers in cell-free microsomal systems (Silbert, 1967; Silbert and DeLuca, 1968) . We used mouse mastocytoma microsomes to establish the nature and order of reactions in heparin biosynthesis, determined in part by the substrate specificities of the various enzymes involved (glycosyltransferase, epimerase, N-and O-sulfotransferases) (Jacobsson and Lindahl, 1980) . A highlight of these studies was the demonstration of L-iduronic acid formation, in heparin/HS as well as in DS, through C5-epimerization of Dglucuronic acid residues in the polymer chain, and not through incorporation from UDP-iduronic acid (as previously suggested) (Lindahl et al., 1972; Malmström and Fransson, 1975) . The experiments were inspired by the discovery of an analogous epimerization reaction (from Dmannuronic acid to L-guluronic acid) in alginate biosynthesis, by a Norwegian group (Haug and Larsen, 1969) . Unfortunately, the concerted mode of action of the biosynthetic enzymes still remains poorly understood. Incompletely modified polymer "intermediates" suggested a partition of the process over separate enzyme complexes (Jacobsson and Lindahl, 1980) , an option still under consideration (Multhaupt and Couchman, 2012) . On the other hand, separation of such complexes over different Golgi domains appears unlikely in view of the finding that a preformed precursor polysaccharide was converted into fully sulfated heparin within 30 s after the addition of PAPS to a mouse mastocytoma microsomal fraction (Höök et al., 1975) . Current notion rather favors a tightly knit Golgi complex of membrane-bound enzymes and substrate -the "GAGosome" (Esko and Selleck, 2002; Dagälv et al., 2011) . We assume (without any solid evidence) that essentially similar arrangement applies to the biosynthesis of HS and, presumably, CS/DS. Although various models have been proposed to account for GAGosome action (Lindahl and Li, 2009; Rudd and Yates, 2012 ) the regulation of such machinery remains an enigma. Whereas HS samples isolated from various murine and bovine tissues all differed in composition and domain organization, samples obtained from similar tissues of syngeneic mice appeared virtually identical (Maccarana et al., 1996; Ledin et al., 2004) . Presumably, these findings reflect a process controlled through the amounts of enzymes and substrate available, in essentially stochastic manner, rather than a template-driven generation of identical, individual HS chains. In accord with this notion, siRNA-mediated reduction in expression of Ndeacetylase/N-sulfotransferase-1, a key regulatory enzyme, was recently found to decrease HS sulfation and modulate HS-dependent signaling mechanisms (Kasza et al., 2013) . On the other hand, HS disaccharide composition was not significantly affected by a N50% reduction in overall Ndeacetylase/N-sulfotransferase activity caused by deletion of Ndeacetylase/N-sulfotransferase-2 (Ledin et al., 2006) , nor by a similar reduction in glucuronyl C5-epimerase activity (Li et al., 2003) . Are auxiliary proteins, devoid of catalytic activity involved in the process? Would sequence analysis of whole HS chains, still beyond reach, help to clarify the overall process? Whatever the regulatory mechanisms behind the generation of cell-specific HS structures, we must assume that the structural diversity has a functional purpose.
Proteoglycan functions
PGs were initially recognized essentially as ubiquitous structural elements, imparting mechanical stability to connective tissues of various kinds. With time they became associated with a variety of processes, as stabilizers of growth factor, morphogen and chemokine gradients, as receptors and co-receptors, pathogen attachment sites etc. (Kjellén and Lindahl, 1991; Bernfield et al., 1999; Bishop et al., 2007; Iozzo and Karamanos, 2010; Nikitovic et al., 2012) . HA, an extended GAG chain devoid of sulfate groups nicely illustrates this transition, as it evolved from a mere space expander into a key player in signaling pathways involved in embryogenesis, morphogenesis, tissue repair, inflammation, and cancer (Hascall and Karamanos, 2011) . Functions of some PGs such as the extracellular HSPG perlecan, depend on the ability of the core protein to interact with other protein ligands (Whitelock et al., 2008) .
Core proteins serve to locate their associated GAG chains at cell surfaces, but also to transduce signals through cell membranes (Alexopoulou et al., 2007) . Cleavage of syndecan protein cores releases soluble, GAG-containing ectodomains that may assume various effector functions (Manon-Jensen et al., 2010) . However, central to most PG functions is the non-covalent interaction between the GAG chains and proteins. The number of GAG-binding proteins revealed during the last few decades of research is staggering, as is the diversity of associated functions. Due to personal bias I will restrict the discussion to conceptual issues of HSPG function that have evolved with time, well aware that similar questions apply also to several CS/DS-mediated phenomena.
HS was identified in Hydra, dated back some 500 million years, and showed structural features quite similar to the present-day GAG . By contrast, hundreds of different proteins have evolved the ability to interact with HS (Ori et al., 2011) . Most of the identified mammalian HS-binding proteins, many with important physiological and patho-physiological roles (Bishop et al., 2007; Lindahl and Li, 2009; Lindahl and Kjellén, 2013) are structurally unrelated, suggesting that their ability to interact with HS arose through convergent evolution. The question of specificity pertaining to such interactions has been a standing issue through the last few decades (Kreuger et al., 2006) . It still remains controversial, not because the level of specificity varies -this is now generally accepted (see, for instance (Le Jan et al., 2012)) -but due to discrepant views on the structural basis for selectivity (Lindahl and Li, 2009 ). The strict regulation of HS biosynthesis suggests a high degree of specificity and selectivity in interactions of HS with proteins. This notion has been underpinned by the interaction between heparin/HS and antithrombin (that contrary to most other interactions depends on a sulfate group in "rare" position), and is commonly referred to in terms of a "sulfation code". There is no reason to rule out that protein binding may critically depend on combinations of sulfate groups located in defined positions in relation to key basic amino-acid residues. However, we suggest that particular constellations of sulfate groups are preferentially established not as predetermined sequences of variously sulfated sugar residues, but rather (along with redundant sulfate residues) through essentially stochastic sulfation reactions (Lindahl and Li, 2009) . The formation of a particular structure might then be considered primarily a statistical matter, controlled through levels of the various polymer-modification reactions, as determined by the abundance of the enzymes involved, their substrate specificities and regulation due to complex formation. This proposal lacks further experimental evidence and does not, for instance, readily explain the presence of the distinct domains typical of a HS chain. Ultimately, we need to unravel the true nature of the GAGosome! Moreover, satisfactory assessment of interaction specificities requires access to libraries of oligosaccharides, of HS and CS/DS type, with systematically varied structure. Methods to produce such compounds, through chemical or chemo-enzymatic synthesis appear within reach Noti et al., 2006; Liu et al., 2010) but the purchase of comprehensive GAG oligosaccharide library kits from Sigma remains a dream of a hazy future. The synthesis of the antithrombin-binding heparin pentasaccharide still stands out as the shining example of the trade (Petitou et al., 2003) .
As knowledge has matured regarding physiological roles of PGs, so has our awareness concerning their pathophysiology. The dramatic growth of this research area in recent decades is largely due to the availability of genetic tools that have led to refined diagnostic methods but also access to transgenic animal disease models. PGs have been variously implicated in infectious and inflammatory diseases, prion disease and amyloidosis, cancer, as well as in a variety of inborn genetic diseases (Bishop et al., 2007; Malavaki et al., 2008; Lawrence et al., 2013; Lindahl and Kjellén, 2013) . Disease conditions may be associated with detrimental interactions between GAG chains and protein protagonists that should be eliminated or weakened in the course of therapy. Conversely, such interactions may need to be reinforced (Lindahl and Kjellén, 2013) . Again, the development of drugs based on oligosaccharides or mimetics has been hampered by the lack of oligosaccharide reagents with sufficiently expanded sequence space.
Proteoglycan genomics
The introduction of transgenic techniques has heavily influenced the PG field (along with virtually all biological sciences). Yet the potential of genetic approaches was not immediately apparent to the PG community; I recall a muttered "stamp collection" when news of the HUGO project surfaced at one of the Gordon PG conferences around 1990. Already in 1985, however, Esko and coworkers heralded the PG genomic era by identifying Chinese hamster ovary cell mutants defective in GAG biosynthesis (Esko et al., 1985) . Their technique, based on screening of replicate cell colonies immobilized on polyester cloth, was refined to allow selection of mutants lacking a particular GAG species (see e.g. Lidholt et al., 1992) , thereby providing valuable tools for functional assessment of, in particular, cell-surface PGs. Further pursuit of GAGrelated genetics revealed staggering complexity. Whereas HS-or CSdeficient cells both thrive in culture, only the latter cells were able to generate tumors in nude mice (Esko et al., 1988) . Moreover, multicellular organisms lacking a particular PG core protein or GAG biosynthetic enzyme were found to present a plethora of phenotypes of variable severity (Bülow et al., 2002; Perrimon and Häcker, 2004; Bishop et al., 2007; Mizumoto et al., 2009) . Current insight into GAG functional genomics dawned only gradually.
Today, genetic tools are indispensable in most aspects of PG research. Compare the relative ease of cloning and defining novel PG core proteins, such as serglycin (Bourdon et al., 1985) or versican (Zimmermann and Ruoslahti, 1989) , with the cumbersome efforts required to determine the amino-acid sequence of cartilage proteoglycan, based on separation and sequencing of peptides generated by cyanogen bromide cleavage (Bonnet et al., 1983) . Transfection of genes encoding core proteins opened novel routes to analysis of PG function. For example, decorin was found to regulate cell growth by interfering with TGFbeta signaling (Yamaguchi and Ruoslahti, 1988; Yamaguchi et al., 1990) or by activating the EGF receptor (Moscatello et al., 1998) . Conversely, targeted deletion of genes encoding core proteins (e.g. Danielson et al., 1997) or even an exon representing a GAG-substituted core-protein domain (Rossi et al., 2003) revealed in-vivo functions of defined proteoglycan or GAG species. Also recombinant peptide fragments, such as endostatin (O'Reilly et al., 1997) and endorepellin (Mongiat et al., 2003) , derived from core proteins of the HSPGs, collagen XVIII and perlecan, respectively, have been expressed and analyzed for biological activity (here anti-angiogenic effects).
Genetics of GAG biosynthetic enzymes has been variously examined and exploited. Knockout or knockdown experiments aimed at elucidating roles of GAGs in development or homeostasis revealed unexpectedly complex patterns. For instance, mice synthesizing HS devoid of iduronic acid residues (due to C5-epimerase knockout) showed some severely perturbed organs, but also morphologically apparently normal tissues known to depend on HS for development (Li et al., 2003) . This result and related findings in other model organisms added to questions regarding specificity in HS-protein interactions (see Section 4) (Kreuger et al., 2006) . Whereas systemic targeting of certain enzymes yield lethal phenotypes, conditional knockout of the same enzymes have been used to pinpoint GAG function in selected cell systems (see, for instance, Bush et al., 2012; Irie et al., 2012) . Diseases associated with mutations in genes encoding GAG biosynthetic (e.g. Stickens et al., 2000) or degradative (Hopwood and Morris, 1990 ) enzymes have been described and are likely to increase in number. Finally, the availability of recombinant enzymes have enabled analysis of threedimensional structure (Liu et al., 2012) , and has greatly facilitated studies on enzyme action and interactions (Pinhal et al., 2001; Carlsson et al., 2008; Presto et al., 2008) . Overall, the rise of PG/GAG genomics has expanded the research area into foreign scientific fields -who would expect to find a collaborator (or competitor) among fly or worm experts in the early 1980's?
Proteoglycan serendipity
Imaginative research projects often take unexpected turns that yield unpredicted results. A few examples (arbitrarily somewhat slanted toward my own research interests) may illustrate the impact of serendipity on PG science. Fratantoni et al. co-cultured fibroblasts from patients with two different GAG storage diseases (mucopolysaccharidoses of the Hurler and Hunter type), and found that the cells could mutually "cure" each other through "factors" released into the medium (Fratantoni et al., 1968) . This key discovery led to our current understanding of GAG metabolism and the complex interplay of lysosomal enzymes involved, to identification of the genetic defects behind the various diseases, and to novel treatment strategies (Hopwood and Morris, 1990) .
Our research group noted that newly synthesized heparin chains in mast cells were considerably longer (60-100 kDa) than those (5-15 kDa) in commercially available heparin preparations. The difference could be ascribed to intracellular action of a specific endo-ß-glucuronidase (Ögren and Lindahl, 1975) , at the time assumed to be specific for mast cells. However, subsequent work by other groups showed that the enzyme, currently known as heparanase, is expressed by most mammalian cells, has HS rather than heparin as the main target, and is a major protagonist in pathophysiological settings such as cancer, inflammation, diabetes, atherosclerosis and other vessel wall pathologies. Interestingly, some of the effects of heparanase appear due to receptor-mediated mechanism(s) rather than cleavage of HS chains.
For recent, comprehensive accounts of heparanase pathophysiology, see a thematic minireview series published in Matrix Biology in 2013, edited by Vlodavsky and Sanderson.
The unpredicted obesity of a transgenic mouse overexpressing the HSPG, syndecan-1 led to elucidation of a previously unknown mechanism in regulation of feeding behavior, involving appetite-stimulating agouti-related protein (AgRP) (Reizes et al., 2001 ). Syndecan-bound HS was found to serve as a co-receptor for AgRP binding to the hypothalamic melanocortin receptor 4, thus inducing feeding. The co-receptor function in nontransfected controls is provided by syndecan-3, with a HS-substituted ectodomain that is released by proteolytic cleavage of the core protein. Proteolysis is regulated, induced by satiety, and dependent on the presence of a specific peptide target sequence in the core protein. This sequence turned out to be missing in syndecan-1.
Mice lacking HS in postnatal neurons, due to conditional inactivation of the glycosyltransferase EXT1 (HS "polymerase"), showed no detectable morphological defects of the brain. Remarkably, however, these mutant mice recapitulated almost the full range of autistic symptoms, including impairment of social interaction and expression of stereotyped, repetitive behavior (Irie et al., 2012) . Further analysis led to the conclusion that HS is critical for the normal functioning of glutamatergic synapses.
Many similar examples could be raised to emphasize the dependence of important discoveries on curiosity-driven basic research. Such discoveries will be promoted by funding agencies that primarily recognize the scientific value of a proposal, rather than a "strategic" goal implying that you already know what you are going to discover. Funding of research projects is a common obstacle, and a likely reason why many PG researchers aim for "strategic platforms" that may provide the money but also unwarranted conceptual bias. In my opinion this policy has gained too much weight.
Concluding remarks
Awareness of the importance of PGs in development, homeostasis and disease has generally stimulated interest in these intriguing macromolecules. Yet the PG community has remained relatively small, with an image of modesty fostered by hard work in a somehow nonglamorous branch of science. From my own view I am surprised at the relative scarcity of scientists devoting their attention primarily to the GAG chains.
Finally, a note on a social aspect of PG scientists and their way of interaction. The field is a friendly one, as readily seen at the Gordon Conference with its open atmosphere, generous attitude toward young scientists, and free exchange of information. It is a field that has allowed me to maintain friendly relations also with my competitors!
